ResMed| Q1 FY2027 results
$239.53+0.27%
ResMed| reported revenue of $1.41 billion, up 5.9% from a year earlier, net income of $418 million and diluted earnings per share of $2.92 against $2.37 for the first quarter of fiscal 2027 (the three months to 30 Sep 2026).
From its quarterly report, the results first announced on 29 Oct 2026. Compiled and checked by AapWire.
Q1 FY2027 against Q1 FY2026
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q1 FY2027 | Q1 FY2026 | Change |
|---|---|---|---|
| Revenue | $1.41B | $1.34B | +5.9% |
| Gross profit | $870.6M | $817.7M | +6.5% |
| Gross margin | 61.5% | 61.2% | +0.3 pts |
| Operating income | $453.0M | $446.5M | +1.4% |
| Operating margin | 32.0% | 33.4% | −1.4 pts |
| Net income | $418.4M | $348.5M | +20.0% |
| Diluted EPS | $2.92 | $2.37 | +23.2% |
| Operating cash flow | $422.4M | $457.3M | −7.6% |
| Capital expenditure | $48.74M | $42.97M | +13.4% |
| Free cash flow | $373.7M | $414.4M | −9.8% |
Operating KPIs for the quarter
| KPI | Q1 FY2027 | Change on a year |
|---|---|---|
| Residential Care Software revenue | $155.0M | down 6.7% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q1 FY2027 | 30 Sep 2026 | $1.41B | +5.9% | $2.92 |
| Q4 FY2026 | 30 Jun 2026 | $1.46B | +8.6% | $2.64 |
| Q3 FY2026 | 31 Mar 2026 | $1.43B | +10.8% | $2.74 |
| Q2 FY2026 | 31 Dec 2025 | $1.42B | +11.0% | $2.68 |
| Q1 FY2026 | 30 Sep 2025 | $1.34B | +9.1% | $2.37 |
| Q4 FY2025 | 30 Jun 2025 | $1.35B | +10.2% | $2.58 |
| Q3 FY2025 | 31 Mar 2025 | $1.29B | +7.9% | $2.48 |
| Q2 FY2025 | 31 Dec 2024 | $1.28B | +10.3% | $2.34 |
More on ResMed|: financial statements · revenue · earnings per share
RMD's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
